MedPath

Re-irradiation of recurrent Glioblastoma withCarbon-Ions (C12) versus Stereotactic Radiotherapy with Photons - A Multicenter, Prospective Randomized Two-Arm Trial

Phase 3
Recruiting
Conditions
C71.9
Brain, unspecified
Registration Number
DRKS00025069
Lead Sponsor
Philipps-Universität Marburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
190
Inclusion Criteria

1. recurrent glioblastoma
2. Karnofsky index of =60%
3. 18 = age > 70 years
4. preceding radiotherapy at primary diagnosis
5. time after re-irradiation >6 months
6. written informed consent

Exclusion Criteria

1. Gliomatosis cerebri
2. distant recurrence
3. involvement of Liquor cerebrospinalis
4. preceding re-radiotherapy of gliablastom
5. patient unable to give consent
6. pregnancy
7. decompensated concomitant disease of the respiratory organs, cardiovascular system, metabolism, hematopoietic system, coagulation or kidney function
8. concurrent participation in other clinical trials that may influence the results of this study
9. active medical implants without authorisation for ion irradiation at the time of treatment (e.g. pacemaker, defibrillator)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary endpoint is overall survival (OS): Survival is defined as the time from randomisation until death from any cause or censoring of survivors at the time of the last documented observation within the study period, whichever occurs first.
Secondary Outcome Measures
NameTimeMethod
- Toxicity of treatment based on the incidence of grade 3-5 NCI-CTC-AE 5.0<br>- Quality of life (quality of life according to EORTC-QLQ-C30, QLQBN20 and BN) <br>- Cortisone demand (mg/d)<br>- Progression-free survival (PFS) according to RANO<br>- Neurocognitive function (Hopkins Verbal Learning Test-Revised)<br>
© Copyright 2025. All Rights Reserved by MedPath